Kineta Inc. Programs Named "Top Projects" Second Year Running  
11/30/2011 9:02:31 AM

SEATTLE--(BUSINESS WIRE)--Kineta’s two lead drug development programs will be honored by the pharmaceutical industry this week for their scientific distinction and likelihood to rapidly progress to high-value partnering deals. Both ShK-186 and r-OAS1, Kineta’s autoimmune and antiviral programs, were named among the “Top Projects to Watch” by Windhover and Elsevier Business Intelligence companies.